


SciTech Development Attending 38th Annual J.P. Morgan Healthcare Conference (GROSSE POINTE FARMS, MI) November 22, 2019 – SciTech Development is pleased to announce that it will be attending the J.P. Morgan Healthcare Conference January 12–16 in San Francisco, CA. SciTech will be participating in the BIO One-on-One Partnering™ @ JPM.

For one-on-one meetings @ JPM contact Earle Holsapple (+1-313-938-5517) or Don Zinn (+1-269-569-2794) to discuss ST-001 nanoFenretinide investment and partnering opportunities. SciTech Development's proprietary nanoparticle drug delivery system (SciTech Drug Delivery Vehicle - SDV) enables intravenous (IV) delivery of water-insoluble (or hydrophobic) drugs. Fenretinide, SciTech's lead API (active pharmaceutical ingredient), has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity; however, its poor bioavailability has impeded its development as a drug. The patented combination of SciTech's new SDV and the fenretinide API has led to the company's lead drug candidate ST-001 nanoFenretinide with enhanced bioavailability (water solubilized) for the treatment of non-Hodgkin's T-cell lymphoma. SciTech is actively seeking funding and strategic partnerships to conduct a Phase 1A & 1B clinical trial to reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide formulation while also confirming a newly identified immune MOA (mechanism of action) as a further goal of the protocol.



**Meet With SciTech Development @ JPM
2020 Jan 12–16 in San Francisco, CA**

Biotechnology Innovation Organization

**ONE
PARTNERING™**

@JPM

About SciTech Development

SciTech Development, LLC is a clinical stage drug development company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options.

SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

For More Information About SciTech: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. In particular, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.



####